By Tom Winnifrith | Wednesday 11 December 2019
By now those who have ploughed almost £30 million into Polat Hassan’s City boiler room scams One True View and Appbox Media which we have exposed on this website of late will have realised that they are set to lose everything. Meanwhile, as the FCA sits around doing nothing I fear this could get much wider, Meet Eden Pharma Ltd.
I am alerted to this company by one victim of the Appbox/One True View scams who says that the same salesman who persuaded hm to back those two schemes and who insists they are both on track, has now advised him that he must not miss out on Eden Pharma, he must invest NOW as the next funding round will be at a far higher price. This sounds rather familiar.
I note, with some concern, that for all its boasts about vast fund raises – as promoted on this paid for article at Proactive – and via the LSE RNS Reach service there have actually been no filings at Companies house about the share issuances as you can see HERE. The only thing that the company seems to have done since incorporation in March of this year is to move tregistered office twice.
And one of those offices rings a bell: 10-12 Bourlet Close London W1W 7BR. That is an address used by companies linked to Polat Hassan such as Start up Nominees. It is, in fact the address of Nicholas Peters & Co, the accountants who sign off on Polat’s companies shocking accounts.
So the same accountants and the same salesman promoting Eden as promoting the Hassan boiler room companies. Inadequate company filings, massive promises of share uplifts and jam tomorrow. The company claims to have a City office but in reality 23 Austion Friars is just a Regus building with space let by the day. Like the Hassan companies it pushes the EIS carrort aggressively.
I have contacted the FCA to alert it to this new company and put this article outside the paywall as a warning to all: Do not invest a cent.
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Search ShareProphets |
Stock market news |
Recent Comments |
Site by Everywhen